Hyperuricemia Therapeutic Market Analysis

The Global Hyperuricemia Therapeutic Market is estimated to be valued at USD 2.2 billion in 2024 and is expected to reach USD 3.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

The market is witnessing positive growth owing to rising geriatric population worldwide who are more prone to develop hyperuricemia. Additionally, changing lifestyle and diet patterns have led to increased prevalence of obesity and metabolic disorders such as hyperlipidemia and hypertension. Since high uric acid is often associated with such comorbidities, the number of patients seeking effective treatment has surged in recent times. Furthermore, numerous pipeline drugs for long-term management of hyperuricemia condition are under development which upon successful approval may cater to huge unmet needs. However, patent expiries of major drugs may impede the market revenue to a certain level during the forecast period. Overall, increasing awareness about Hyperuricemia complications and benefits of early intervention is expected to drive the global Hyperuricemia Therapeutic Market.